BTIG Reiterates Buy Rating on EOLS
BTIG maintains its bullish stance on EOLS, setting a price target of $13, a 96.08% upside from the current price.
Key Points
- BTIG reiterated its buy rating on EOLS with a $13 price target on June 17, 2026.
- BTIG's $13 price target implies 96.08% upside from Evolus, Inc.'s ($EOLS) current $6.63 share price.
- Shares of EOLS traded at $6.63, with notable institutional activity from Nantahala Capital and BlackRock.
- Insiders like David Moatazedi and Rui Avelar engaged in planned stock sales earlier in the year.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG reiterated its buy rating on EOLS, setting a price target of $13 on June 17, 2026. This reiteration reflects continued confidence in the company's potential, with EOLS shares currently trading around $6.63.
Other Institutional Activity in EOLS
Several institutional investors have been active in EOLS. Nantahala Capital Management added 556,208 shares to its holdings, now owning 6,376,857 shares valued at approximately $26.2 million. BlackRock, Inc. also increased its stake by 195,083 shares, bringing its total to 4,290,383 shares worth about $17.6 million. Meanwhile, Braidwell LP and Frazier Life Sciences Management maintained their positions, holding 3,105,209 and 2,630,665 shares, respectively. Vanguard Capital Management initiated a new position with 2,470,408 shares valued at $10.2 million, and Soleus Capital Management significantly boosted its stake by 1,175,360 shares, reaching a total of 2,245,360 shares.
Insider Buying and Selling at Evolus, Inc.
Insider activity at EOLS included several transactions earlier this year. On March 20, 2026, David Moatazedi, President and CEO, sold 13,669 shares at an average price of $4.75 as part of a planned sale. Rui Avelar, Chief Medical Officer and Head of Research & Development, sold 3,119 shares at $4.75 on the same day without a pre-arranged plan. Previously, on March 17, 2026, Moatazedi and Avelar executed planned sales, with Moatazedi selling 116,720 shares at $4.89 each, and Avelar selling 29,996 shares at the same price. On March 16, 2026, both insiders also made purchases, with Moatazedi acquiring 67,489 shares and Avelar buying 8,804 shares.
Analysts Set New Price Targets
On June 17, 2026, BTIG reiterated its buy rating for EOLS, setting a price target of $13. Earlier in the year, HC Wainwright & Co. maintained its buy rating with the same target on February 3, 2026. Other analysts have shown optimism as well, with Stifel maintaining a buy rating and a higher target of $17 on January 13, 2026. Overall, the consensus among analysts is a buy rating, with an average target price of around $13, based on multiple opinions.
About EOLS
EOLS operates in the healthcare sector, focusing on the development and commercialization of innovative medical products. The company is known for its work in aesthetic and therapeutic applications, aiming to bring new treatments to market. Headquartered in the United States, EOLS is led by a team of experienced executives and employs a dedicated workforce committed to advancing healthcare solutions.
Bottom Line
BTIG's reiterated buy rating and $13 price target suggest ongoing confidence in EOLS's future prospects. Institutional investors are actively adjusting their positions, indicating interest in the company's potential. Insider transactions, while planned, show active engagement from key executives. As always, it's important to remember that these analyst ratings and institutional moves are based on past data and may not reflect current conditions.
Get Evolus, Inc. alerts
New 13F filings, insider trades, and analyst moves on $EOLS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.